ReachMD CME

CME credits: 0.75 Valid until: 08-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/small-ball-wins-games-combination-therapy-for-goal-attainment/56438/ This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD...

CME credits: 0.75 Valid until: 08-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/swing-for-the-fences-ldl-c-as-the-power-hitter/56437/ This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series f...

CME credits: 0.75 Valid until: 08-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/leadoff-hitter-spotting-high-risk-players/56435/ This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuse...

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/serena-6-acting-on-esr1-mutations-in-advanced-breast-cancer/57229/ Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded o...

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/ongoing-trials-in-oral-targeted-strategies-in-breast-cancer/57228/ Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded o...

CME credits: 0.50 Valid until: 23-07-2027 Claim your CME credit at https://reachmd.com/programs/cme/elevate-elacestrant-plus-capivasertib-in-advanced-breast-cancer/57227/ Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expand...

CME credits: 1.00 Valid until: 04-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/a-q-challengetm-replay-advancing-precision-diagnosis-and-treatment-strategies-in-acromegaly/49278/ This broadcast replay from AACE 2026 features an interactive, case-based Q-Challenge format focused on acromegaly. Participants engage with clinical scenarios designed to assess and reinforce diagnosti...

CME credits: 0.25 Valid until: 03-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/first-5-minutes-empowering-shared-decisions-in-lung-cancer-screening/50985/ This episode focuses on improving lung cancer screening and early detection by helping primary care providers recognize eligible and high-risk patients, apply current screening guidelines, and engage patients in clear shared...

CME credits: 2.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-il-23-pathways-evolving-biologic-strategies-in-ibd/60779/ This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations,...

CME credits: 2.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/gut-selective-therapy-understanding-anti-integrins-in-ibd/60778/ This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and...

CME credits: 2.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/revisiting-anti-tnfs-role-risks-and-real-world-considerations/60777/ This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations,...

CME credits: 2.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-one-size-fits-all-individualizing-first-line-ibd-treatment/60776/ This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerati...

CME credits: 2.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/where-conventional-ibd-therapies-fall-short/57256/ This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-speci...

CME credits: 2.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/defining-success-in-ibd-treat-to-target/57255/ This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific...

CME credits: 1.00 Valid until: 02-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/seeing-the-invisible-radiologic-precision-to-enable-early-intervention-in-bronchiectasis/56384/ Bronchiectasis is a chronic, progressive respiratory disease that is characterized by accelerated lung function decline and impaired quality of life, yet it remains substantially under recognized and unde...

CME credits: 2.00 Valid until: 30-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/setting-the-stage-why-rethinking-ibd-care-matters-now/56325/ This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and pat...

CME credits: 0.25 Valid until: 01-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-her2-in-solid-tumors-from-pathology-to-personalized-treatment-plans/54582/ Dr. Kathleen Moore reviews the clinical significance of HER2 expression across diverse solid tumors and its role in guiding treatment decisions. She outlines HER2 testing methodologies, including immu...

CME credits: 0.25 Valid until: 01-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/chairpersons-perspective-reframing-first-line-and-subsequent-care-in-advanced-urothelial-carcinoma-clinical-implications-of-the-updated-nccn-guidelines/54396/ This 15-minute online CME activity reviews the clinical implications of the updated NCCN Guidelines for advanced urothelial carcinoma (aUC),...

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/all-hands-on-deck-multidisciplinary-coordination-for-smarter-perioperative-care/57093/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary an...

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/turning-evidence-into-action-applying-perioperative-data-to-real-world-practice/57091/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary an...

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/partnering-through-treatment-preparing-for-immunotherapy-in-the-perioperative-setting/57090/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert comment...

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/choosing-the-path-forward-a-real-world-dialogue-on-perioperative-immunotherapy/57089/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and...

CME credits: 0.50 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/before-the-scalpel-identifying-candidates-for-perioperative-immunotherapy/57086/ This online CME activity uses a patient–clinician dialogue format to explore the evolving role of perioperative immunotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC). Expert commentary and pati...

CME credits: 1.00 Valid until: 29-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/cushing-syndrome-strategies-diagnosis-management/39896/ This webinar aims to give learners a case-based exploration of hypercortisolism/Cushing Syndrome (CS) care, covering screening, diagnosis, referral, and treatment. It will closely examine how to identify and screen for atypical presentations of...

CME credits: 0.25 Valid until: 27-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/diagnose-hypercortisolism-cardiometabolic-conditions/50069/ With an updated understanding of how common hypercortisolism is among patients with hard-to-manage cardiometabolic conditions, what are the implications for clinical practice? How can healthcare providers determine who should be screened, c...